The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer. by Hall, N. R. et al.
Br. I. Cancer (1994), 7e, 549-553
The role of CA-242 and CEA in surveillance following curative resection
for colorectal cancer
N.R. Hall', P.J. Finan', B.M. Stephenson', D.A. Purves2 & E.H. Cooper2
'Department ofSurgery and Centrefor Digestive Diseases, General Infirmary at Leeds, Great George Street, Leeds lS] 3EX,
UK; 2Diagnostic Development Unit, Department ofChemical Pathology, University ofLeeds, Leeds LS2 9JT, UK.
This study was undertaken to evaluate the role of a new tumour marker, CA-242, alone or in
combination with CEA in the practcal management of colorectal cancer patients after potentialy curative
resection. A cohort of 149 patients who had 'cative' surgery was foDowed up aong to an
intensive protocol in order to detect recurrent diseas. Over a median tumour marker follow-up perod of 24
months there were 25 rmecurences in 24 patients. Both CEA and CA-242 alone detected half the local
McurenCeS. The sensitivity ofCEA was 84% for distant or mixed recurren d with 64% for CA-242.
An abnormality of other CEA or CA-242 enabled detecto of five out of six local recurres and 17 out of
19 distant or mixed ecurnces with a mecian kad time of 5 months for each marker. Both markers were
elevated concurrently in only one lcal and 11 distant recurrences. While CA-242 alone is not superior to
CEA, their combned use (either abnormal) has a high sensitity (88%), speciiity (78%) and netive
predive value (97%); this may be useful in reducing innssary ivestigations in follow-up programn
and as a guide to the initiation of further treatment for recurrent disa.
In the management of colorectal cancer operative findings,
pathological stage and preoperative carcinoembryonic anti-
gen (CEA) levels are strong prognostic indicators that are a
guide to the likelihood of cure (Dukes & Bussey, 1958;
Wanebo et al., 1978). However, following potentially curative
surgery there is a period of uncertainty as to whether the
operation has cured the cancer in an individual patient.
Treatment failure will usually become apparent during the
first 2-3 years after surgery (Aldridge et al., 1986; Sugar-
baker et al., 1987).
The precise post-operative surveillance procedures and
their frequency vary but are based on clinical assessment,
endoscopy, ultrasound and computerised tomography (Cl)
depending on the site of primary tumour. Many clinicians
will include the measurement of CEA as an essential investi-
gation in the detection of asymptomatic recurre of colo-
rectal cancer. Those surgeons who advocate the use of
second-look surgery advise that CEA should be measured
every 6-8 weeks so that a suspicious rising level can be
identified as early as possible (Staab et al., 1985; Minton &
Chevinsky, 1989); for others 3 monthly CEA testing during
the high-risk period of the first 2 years after resection tends
to be the rule with a reduction in frequency of testing
thereafter (Hine & Dykes, 1984).
It is evident that while CEA monitoring during the follow-
up of patients after potentially curative surgery is valuable it
lacks the sensitivity and specificity to be an infallible guide to
the patient's status (Northover, 1986). Metastatic disease or
local recurrence may produce symptoms or signs without a
concurrent rise in CEA.
During recent years new generations of markers for gastro-
intestinal cancer, based on mucins, have become available as
commerial test kits. They include CA-50 (Holmgren et al.,
1984), CA-19-9 (Del Villano et al., 1983), CA-195 (Barghava
et al., 1987) and CA-242 (Nilsson et al., 1992), all of which
have been shown to be valuable in pancreatic cancer
(Kuusela et al., 1991; Taylor et al., 1992; Pasanen et al.,
1993) and have been suggested as markers in colorectal
cancer. When used in combination with CEA, CA-19-9
(Quentmeier et al., 1987) and CA-195 (Sagar et al., 1991;
Ruggeri et al., 1993) have been shown to provide a gain of
positivity in colorectal cancer. The recent studies of CA-242
showed that it has a higher sensitivity than CA-50 in primary
colorectal cancer and a low false positivity in benign liver
disease (Kuusela et al., 1991; Nilsson et al., 1992). In prinary
colorectal cancer, additional use of CA-242 improves the
diagnostic sensitivity of CEA alone (though it still remains
limited) (Roberts et al., 1992), and CA-242 has also been
shown to compklment CEA monitoring of patients reiing
chemotherapy for liver metasta from colorectal cancer
(Ward et al., 1993). In this paper we report an evaluation of
the combination of CEA and CA-242 in the post-operative
monitoring of patients with colorectal cancer after curative
surgery to assess the clinical utility of these markers in a
well-defined group of patients.
PadeUs and
We studied a cohort of patients who underwent laparotomy
for colorectal carcinoma under the care of one surgeon
(PJ.F.) 1987 and 1991. Of the 246 consecutive
patients treated in this period, 58 underwent a paliative
procdure and are exduded: 22 of these had macroscopic
residual disease remaining and 36 had evident metastai
disea at surgery. Thirty-nine further patients are excld
owing to early death preventing tumour marker follow-up or
insufficient follow-up data. This leaves 149 patients who form
the study group. All of these fulfil the following entry criteria
for the study: 'curative' resection (surgical excision of all
macroscopic disease), measurement of tumour markers on
three or more occaons post-operatively and follow-up to
recurrece, death or at kast 6 months after the last tumour
marker estimation inuded in the study. There were 68 males
and 81 femals with a median age of 70 years (range 37-87)
and 72 years (range 42-86) re ely. Tumour site and
Dukes' staging are shown in Table I.
Patients underwent a andard post-operative survillance
protocol involving outatient attendance for clinihcalamin
ation, faecal occult blood testing and tumour marker estima-
tion every 3 months for the first 2 years, then 6 monthly.
Liver ultrasound was performed every 6 months for the first
2 years, and for rectal tumours a pelvic CT scan was carried
out annually. Colonoscopy was performed at I and 3 years
after the operation, the first examination being earlier if a
good-quality double-contrast barium enema had not been
obtaied pnor to surgery. Patients were also investigated if
there was a clinical suspicion of recurrent disease. The
median follow-up period of tumour marker estimation was
Correspondence: N.R. Hall, Imperial Cancer Research Fund,
Genetic Epidemiology Laboratory, St James's University Hospital,
Beckett Street, Leeds LS9 TrF, UK.
Received 22 December 1993; and in revised form 15 April 1994.
Br. J. Camw (1994), 70, 549-553 ( Macmfflan Pres Ltd., 1994550 N.R. HALL et al.
Table I Tumour site and Dukes' staging
Tunour site'
Dukes' stage Right colon Left colon Rectwn Total (%)
A 3 9 16 28 (19)
B
C
D
29
10
0
25
11
2
24
20
0
78 (52)
41 (28)
2 (1)
Totals 42 47 60 149
'Right colon, caecum to transverse colon; left colon, splenic flexure to rectosigmoid
junction.
24 months and the clinical follow-up was for a median of 34
months.
CEA was measured by Hybritech two-site immunoradio-
metric Tandem CEA-RIA kits (Nottngham, UK) and CA-
242 was measured using a dissociation-enhanced lanthanide
fluoroimmunoassay (DELFIA, Wallac Oy, Turku, Finland).
The upper limits of normal for these assays in our laboratory
are 3ngml'1 for CEA and 20unitsml[l for CA-242.
Tumour marker levels were considered to be abnormal as
follows: a single CEA level over lOngml-1 or three succes-
sively rising levels over 3 ng ml '; a single CA-242 over
40 units mlnl or three successively rising values over
20 units ml-1.
Results
Recurrent disease
During follow-up there were 25 recurrences in 24 patients
(16% of the cohort); one patient had an umbilical recurrence
excised and later developed further abdominal wall recur-
rence and liver metastases. The sites of recurrnce are shown
in Figure 1 and the distribution according to Dukes' stage is
tabulated in Table II. Recurrent disease occurred in three of
the patients with Dukes' A tumours: one developed gross
para-aortic lymphadenopathy but no evidence of liver meta-
stasis, while the other two developed metastases in the lung,
one also with liver secondaries. In the last two, histological
inspection of the excised specimen demonstrated tumour per-
meation into vascular clefts within the muscularis propria.
Both patients with Dukes' D tumours developed recurrence
at the site of the distant disease excised at the original
operation (the liver in one patient and the pelvis in the
other). Twelve of the patients with rectal cancer developed
recurrent disease (three locoregional only, one combined
local and distant and eight distant disease only). The 13
recurrences in 12 patients with colonic primaries were as
follows: three locoregional only, three mixed locoregional
and distant and seven distant only. Median time to first
recurrence was 17.5 months (range 8-23) for local only
recurrences and 14.5 months (range 6-32) for distant or
mixed local and distant recurrences.
One patient with pelvic recurrence was treated with radio-
therapy and one patient with liver metastasis underwent a
course of chemotherapy. Two patients had curative excision
of umbilical recurrence. Three patients had elective second-
look surgery and a fourth underwent emergency laparotomy
for small bowel obstruction: all had unresectable disease. The
only patient with a solitary liver metastasis declined further
surgery. The remaining patients with recurrent or metastatic
disease were treated symptomatically.
Tumour marker abnormalities
During the study period markers were abnormal, as defined
above, in 49 patients. Two strategies for the use of CEA and
CA-242 in conjunction were adopted, with a positive test
being counted either (a) when either marker is abnormal or
(b) when both are abnormal. One or other marker was
abnormal in 27 of 125 (22%) patients with no recurrence,
Table n Sites of recurrence according to Dukes' stage at
presentation
Recurrence
Dukes' stage None Local/regional Distantlmixed Recurrence (%)
A 25 0 3 11
B 67 4 7 14
C 33 2 6 20
D 0 0 2 100
Totals 125 6 18
Local disease Liver Lung
Abdomina
or
intra-abdo
Figwe 1 Sites of 25 recurrences in 24 patients.
five of six (83%) patients with local recurrence and in 17 of
18 (89%) patients (18 of 19 recurrences) with distant or
mixed local and distant recurrence (Table III). Both markers
were elevated in only one patient with local recurrence and
11 of the patients who developed distant or mixed recur-
rence.
CEA became abnormal in all patients who developed re-
current disease, either before or after recurrence had been
diagnosed. In 17 the abnormality preceded clinical, histo-
logical or radiological confirmation of rerrent disease with
a median lead time of 5 months (range 1-15). In two
patients recurrence and CEA abnormality coincided. CA-242
did not rise to fulfil the criteria of abnormality in two
patients with local disease and three patients with distant
disease. In 14 it preceded confirmation of recurrence with a
median lead time of 5 months (range 1-18).
The parameters quantiffying accuracy of CEA and CA-242
alone or combined in the detection of recurrent (local and/or
distant) colorectal carcinoma are shown in Table IV. CA-242
had a lower sensitivity than CEA (60% vs 76%) for recurrent
disease. Specificity and positive and negative predictive values
were each very similar for CEA and CA-242. Use of the
'either abnormal' strategy leads to a high sensitivity of 88%,
a dimunution of specificity to 78% while the false-negative
rate (1-negative predictive value) falls to only 3%. For the
'both abnormal' approach the sensitivity falls to only 48%
with a rise in specificity, positive predictive value and
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Tabl M CEA and CA-242 abnormalities according to presence and site of recurrent
colorctal carcnoma
Recurrence
None Local/regnal Distant/mixed
Tumour marker (n = 125) (n =6) (n = 19, 18 Patients)
CEA abnormality'
Isolated 6 3 14
Rising 14 2 12
Either 17 (14%) 3 (50%) 16 (84%)
CA-242 abnormality'
Isolated 13 3 12
Rising 8 3 5
Either 16 (13%) 3 (50%) 12 (63%)
CEA and CA-242 abnormal 6 (5%) 1 (17%) 11 (58%)
CEA or CA-242 abnormal 27 (22%) 5 (83%) 17 (89%)
'Definitions of tumour marker abnormalities: CEA, isolated vahle >10 ngml', three
rising values over 3ngml '; CA-242, isolated value >40Uml-', three rising values over
20 Uml1.
Table IV Five m urements of acuracy for CEA and CA-242 alone or in combination in the
detection of recurrent colorectal carcinoma
CEA and CA-242 combind (%)
CEA alone (%) CA-242 alone (%) Both abnormal Eitr abnormal
Sensitivity 76 60 48 88
Speificity 86 87 95 78
Positive predictive value 53 49 67 45
Negative predictive value 95 92 90 97
False-neative rate 5 8 10 3
Overall acuracy 85 83 87 80
Reports of tumour marker abnormalities depend critically on
the criteria used to define the abnormality. For single
measurements (e.g. preoperative levels) it is possible to com-
pare the specificity and sensitivity of two tests independently
of the cut-off level used to define the abnormality by using
receiver operating characteristic (ROC) curve analysis
(Pasanen et al., 1993; Zweig & Campbell, 1993). It may also
facilitate the choice of appropriate cut-off kevel. The nature
of serial tumour marker estimations, however, is such that a
level may fluctuate, sometimes excessively, often peaking
above the reference range before returing below it in the
absence of any recurrent cancer. By contrast, a steadily rising
level is much more suggestive of the presence of malignant
tissue, even if the absolute value may not be greatly elevated.
Sometimes the growth of tumour is rapid and a suddenly
high level may be the first indication of current disease.
Different authors have adopted differing solutions to this
problem, some relying on a single elevated level (Beart &
O'Connell, 1983; Hine & Dykes, 1984), some on a trend
(Staab et al., 1985; Sugarbaker et al., 1987), and others using
more complicated analytical methods (Martin et al., 1977).
This issue was addressed specifically by Denstman et al.
(1986), but although some form of slope analysis was recom-
mended in preference to an absolute cut-off value no firm
guidein could be offered. In tlis study we adopted a
definition combining the two decision methods (see section
on tumour marker esimation) with emphasis on simplicity
and ease of use in a clinical setting.
Carcinoembryonic antigen was first described by Gold and
Freedman (1965) and for colorectal carcinoma it remains,
nearly 30 years later, the gold standard by which new
markers arejudged. The current study confirms the reliability
of CEA levels as a guide to recurrent dis, though there
remains the problem, experinced by others (Northover,
1986), that in 14% of the patients without recurrence there
was also an abnormality of CEA (Table Ill). CA-242 per-
formed very similarly to CEA though with a reduced sen-
sitivity. Neither marker was as good in the detection of local
recurrence as distant, though the numbers are too small to
make firm conclusions about which test was superior for
local disease detection. Although the majority of patients
with recurrene had concomitant rise of CEA and CA-242,
there were instances in which one marker mained normal
while the other rose; thus the use of the two in combination
(either abnormal) increased the sensitivity to 88% (Table IV).
This is achieved at the expense of reduced specificity and an
increased rate of false positivity. A strategy requiring both
markers to be abnormal, while having a high specificty for
the detection of recurrence, has an unacceptably low sensi-
tivity of only 48% and is unlikely to be of practical
value.
A major drawback of the early diagnosis of recurrent
colorectal cancer is the present lack of an effective treatment
for the majority of patients. For some, resection of a local
recurrene can be curative, and even where there are distant
metastases (if few in number) resection may improve prog-
nosis. For the majority of patients, however, early diagnosis
may only lengthen the period ofanxiety before death. In our
cohort only 2 ofthe 16 patients with recurrent disease under-
went potentially curative surgery (both had umbilical disease
resected) and one of these remains well 2 years later with no
sign of fturther disease. Neither patient had elevated tumour
marker levels at diagnosis ofrecurrence. To take the nihistic
view that early diagnosis is of no value, however, would be
to negate future advances in treatment and the positive
benefits to patients of knowing their destiny.
Initial enthusiasm that CEA-assisted detection of recurrent
disease might improve the ability of second-look radical
surgery to provide a lasting cure has been tempered by the
overall results from some studies (Beart & O'ConnelL 1983).
A multicentre trial in the UK addressing this issue is nearing
completion. Previous reports show that only about half the
patients who undergo second-look surry have resectable
disease, though the proportion who have further potentially
curative surgery is higher in patients with asymptomatic
recurrene detected by CEA; survival in the latter group is552 N.R. HALL et al.
also improved (Minton et al., 1985; Staab et al., 1985; Quent-
meier et al., 1990).
The role of tumour markers extends wider than as an
indicator for further surgery. Firstly, the follow-up of colo-
rectal cancer by regular haematological, biochemical and
radiological investigation is costly and the majority of in-
vestigations are normal (Sugarbaker et al., 1987). Cost-
effectiveness may be improved by the use of CEA (or other
tumour marker) directed investigation (Wanebo et al., 1989).
Our results show that a normal CEA or CA-242 is rarely
seen in the presence of recurrent disease, whereas tumour can
eventually be demonstrated in about half the patients in
whom either tumour marker is abnormal (positive predictive
value 49-51%). This rather low positive predictive value
may be considered acceptable given the low false-negative
rate. It is clear that CA-242 alone is inferior to CEA as a
tumour marker, though it may serve to complement CEA in
the follow-up after curative resection for colorectal cancer. In
a setting in which investigations were marker directed (as
opposed to routine) there might be a significant advantage in
having a dual tumour marker assay to give the required high
sensitivity, accepting that there may also be an increased
negative investigation rate. We are currently examining a
larger cohort of patients to evaluate such a policy.
Secondly, specificity of production of the CEA and CA-
242 antigens by malignant tissue has opened the possibility
for targeting other molecules at the cancer itself by coupling
them with antibodies to these epitopes. For example,
Pseudomonas exotoxin coupled to C242 (the antibody that
recognises the antigen CA-242) has been effective against a
human colorectal cancer xenograft in nude mice (Debinski et
al., 1992).
A third, and as yet unexplored, avenue relates to the use of
newer therapies directed against recurrent disease. If second-
look surgery has failed to gain general support owing to the
relatively small proportion of patients who derive benefit,
then perhaps a low-toxicity chemotherapy regimen may
prove to be advantageous in patients who develop elevated
tumour markers. Currently the American National Institutes
of Health (1990) recommends adjuvant chemotherapy
(Moertel et al., 1990) for a subgroup of patients with colorec-
tal cancer in the knowledge that even without chemotherapy
half may have a lasting cure. On the basis that chemothera-
peutic agents are most effective in the presence of minimal
disease there is an argument for treating patients who have a
rise in tumour marker levels even before recurrence is
demonstrated radiologically or clinically. We have confirmed
a median lead time of raised tumour markers of 5 months
before recurrence is detectable by other methods of investiga-
tion, and treatment at such an early stage is likely to maxi-
mise the potential benefit. Unfortunately, this would also
mean treating about half the patients unnecessarily, but that
may be acceptable provided the toxicity was minimised. As
chemotherapeutic regimens improve, the importance of
tumour markers as an indication for therapy will probably
increase.
For the reasons above, coupled with the results of this
study, we feel that an approach using tumour markers in
combination is likely to improve their value in the follow-up
of colorectal carcinoma.
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